Literature DB >> 8153400

Lupus nephritis. Classification, prognosis, immunopathogenesis, and treatment.

J Golbus1, W J McCune.   

Abstract

There is great variation in the characteristics of renal histology, in its clinical expression and clinical course, and, most likely, in the pathogenic mechanisms of glomerular damage. As the ability to more precisely characterize these lesions improves and as we better understand the multiple pathogenic mechanisms and modulating factors at play in the disease, treatment advances and improved renal survival should follow.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8153400

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN: 0889-857X            Impact factor:   2.670


  18 in total

1.  Down-regulation of pathogenic autoantibody response in a slowly progressive Heymann nephritis kidney disease model.

Authors:  Arpad Z Barabas; Chad D Cole; Arpad D Barabas; Rene Lafreniere
Journal:  Int J Exp Pathol       Date:  2004-12       Impact factor: 1.925

2.  Predictive value of remission status after 6 months induction therapy in patients with proliferative lupus nephritis: a retrospective analysis.

Authors:  Min Wook So; Bon San Koo; Yong-Gil Kim; Chang-Keun Lee; Bin Yoo
Journal:  Clin Rheumatol       Date:  2011-05-20       Impact factor: 2.980

3.  Urinary N-acetyl-beta-D-glucosaminidase (NAG) in lupus nephritis and rheumatoid arthritis.

Authors:  Dilek Erdener; Kenan Aksu; Ilhan Biçer; Eker Doğanavşargil; Fatma Z Kutay
Journal:  J Clin Lab Anal       Date:  2005       Impact factor: 2.352

4.  EULAR randomised controlled trial of pulse cyclophosphamide and methylprednisolone versus continuous cyclophosphamide and prednisolone followed by azathioprine and prednisolone in lupus nephritis.

Authors:  C-S Yee; C Gordon; C Dostal; P Petera; J Dadoniene; B Griffiths; B Rozman; D A Isenberg; G Sturfelt; O Nived; J H Turney; A Venalis; D Adu; J S Smolen; P Emery
Journal:  Ann Rheum Dis       Date:  2004-05       Impact factor: 19.103

5.  Lupus nephritis among 624 cases of systemic lupus erythematosus in Riyadh, Saudi Arabia.

Authors:  Abdurahman Saud Al Arfaj; Najma Khalil; Salman Al Saleh
Journal:  Rheumatol Int       Date:  2009-04-21       Impact factor: 2.631

6.  Increased excretions of glycosaminoglycans and heparan sulfate in lupus nephritis and rheumatoid arthritis.

Authors:  Ilhan Biçer; Kenan Aksu; Zuhal Parildar; Tijen Tanyalçin; Eker Doğanavşargil; Fatma Z Kutay
Journal:  Rheumatol Int       Date:  2003-03-12       Impact factor: 2.631

7.  An in vitro assay for detection of glomerular binding IgG autoantibodies in patients with systemic lupus erythematosus.

Authors:  L Budhai; K Oh; A Davidson
Journal:  J Clin Invest       Date:  1996-10-01       Impact factor: 14.808

8.  Intensified, intermittent, low-dose intravenous cyclophosphamide together with oral alternate-day steroid therapy in lupus nephritis (long-term outcome).

Authors:  Meral Calguneri; Zeynep Ozbalkan; M Akif Ozturk; Sule Apras; A Ihsan Ertenli; Sedat Kiraz
Journal:  Clin Rheumatol       Date:  2006-03-18       Impact factor: 2.980

Review 9.  Disparities in lupus care and outcomes.

Authors:  Kristina L Demas; Karen H Costenbader
Journal:  Curr Opin Rheumatol       Date:  2009-03       Impact factor: 5.006

10.  Preventative and therapeutic vaccination to combat an experimental autoimmune kidney disease.

Authors:  Arpad Z Barabas; Chad D Cole; Arpad D Barabas; Rene Lafreniere
Journal:  Biologics       Date:  2007-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.